PR Newswire Europe - Warner Chilcott and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea.
FAJARDO, Puerto Rico and BOSTON, July 9 /PRNewswire/ —
Warner Chilcott Company, Inc. and Paratek Pharmaceuticals, Inc. announced today that the two companies have entered into an exclusive license agreement for the development and commercialization of novel, narrow-spectrum tetracyclines for the treatment of acne and rosacea.
Related Results
TetracyclinesTetracyclinesNew Uses for an Old Drug: Rebirth of the TetracyclinesTetracycline diffusion through bacterial cellulose—polyvinyl alcohol…Tetracycline Derivative Induces Lupus
Tetracycline antibiotics are the leading approved systemic treatments of moderate to severe inflammatory acne. Discovered decades ago as broad-spectrum systemic antibiotics, tetracyclines have been shown to be potent anti-acne agents. Paratek has utilized …
Read the rest of this article with a Free Trial at HighBeam Research.
